41 related articles for article (PubMed ID: 1500268)
1. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.
Yao K; Gietema JA; Shida S; Selvakumaran M; Fonrose X; Haas NB; Testa J; O'Dwyer PJ
Br J Cancer; 2005 Dec; 93(12):1356-63. PubMed ID: 16333244
[TBL] [Abstract][Full Text] [Related]
2. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer.
Louie KG; Hamilton TC; Shoemaker RH; Young RC; Ozols RF
Invest New Drugs; 1992 Jul; 10(2):73-8. PubMed ID: 1500268
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
Rickardson L; Kutvonen E; Orasniemi S; Högberg M; Kallio MJ; Rehnmark S
Drug Des Devel Ther; 2017; 11():1335-1351. PubMed ID: 28496304
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing].
Sagawa T; Yamashita K; Kawamura M; Shimizu T; Haga H; Yorozu Y; Kasamo M; Fujita M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1197-204. PubMed ID: 2411831
[TBL] [Abstract][Full Text] [Related]
9. Cloning of human ovarian cancer cells in soft agar from malignant and peritoneal washings.
Ozols RF; Willson JK; Grotzinger KR; Young RC
Cancer Res; 1980 Aug; 40(8 Pt 1):2743-7. PubMed ID: 7388825
[No Abstract] [Full Text] [Related]
10. The National Cancer Chemotherapy Program.
Frei E
Science; 1982 Aug; 217(4560):600-6. PubMed ID: 7046055
[TBL] [Abstract][Full Text] [Related]
11. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
12. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.
Hamilton TC; Young RC; Ozols RF
Semin Oncol; 1984 Sep; 11(3):285-98. PubMed ID: 6385258
[No Abstract] [Full Text] [Related]
13. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.
Hamilton TC; Young RC; Louie KG; Behrens BC; McKoy WM; Grotzinger KR; Ozols RF
Cancer Res; 1984 Nov; 44(11):5286-90. PubMed ID: 6333272
[TBL] [Abstract][Full Text] [Related]
14. Application of a human tumor colony-forming assay to new drug screening.
Shoemaker RH; Wolpert-DeFilippes MK; Kern DH; Lieber MM; Makuch RW; Melnick NR; Miller WT; Salmon SE; Simon RM; Venditti JM
Cancer Res; 1985 May; 45(5):2145-53. PubMed ID: 3986767
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
